lancet-header

Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.

Sec62 Promotes Early Recurrence of Hepatocellular Carcinoma Through Activating Integrinα/CAV1 Signaling

28 Pages Posted: 19 Jun 2019

See all articles by Juan Du

Juan Du

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Hetong Zhao

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Dong Liu

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Hui Liu

Government of the People's Republic of China - Navy Military Medical University

Jun Chen

Fudan University - Liver Cancer Institute

Binbin Cheng

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Xiaofeng Zhai

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Zifei Yin

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Yani Zhang

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Changquan Ling

Government of the People's Republic of China - Department of Traditional Chinese Medicine

More...

Abstract

Background: Postsurgical recurrence within 2 years is the major cause of poor survival of hepatocellular carcinoma (HCC) patients. However, the molecular mechanism underlying HCC recurrence remains unclear. Here, we distinguish the function and mechanism of Sec62 in promoting HCC recurrence.

Methods: The correlation between Sec62 and early recurrence was demonstrated in 60 HCC samples from a prospective study. HCC cells with Sec62 knockdown (Sec62KD) or overexpression (Sec62OE) were used to determine the potential of Sec62 in cell migration in vitro. Microarray analysis comparing Sec62KD or Sec62OE to their control counterparts was used to explore the mechanisms of Sec62-induced recurrence. A luciferase-labelled orthotopic nude mouse model of HCC with Sec62KD or Sec62OE was used to validate the potential of Sec62 in early HCC recurrence in vivo.

Findings: High expression of Sec62 was positively correlated with surgical recurrence in clinical HCC samples. Multivariate analysis revealed that Sec62 was an independent prognostic factor for early recurrence in postoperative HCC patients. Moreover, Sec62 promoted migration and invasion of HCC cells in vitro and postsurgical recurrence in vivo. Mechanically, integrinα/CAV1 signalling was identified as one of the targets of Sec62 in cell movement. Overexpression of integrinα partially rescued the Sec62 knockdown-induced inhibition of cell migration.

Interpretation: Sec62 is a potentially prognostic factor for early recurrence in postoperative HCC patients and promotes HCC metastasis through integrinα/CAV1 signalling. Sec62 might be an attractive drug target for combating HCC postsurgical recurrence.

Funding Statement: This work was supported by the National Nature Science Foundation of China (grant number: 81473484) and the Nature Science Foundation of Shanghai (grant number: 14ZR1408400).

Declaration of Interests: The authors declare that they have no conflict of interest.

Ethics Approval Statement: The animal protocols were performed in agreement with the SIBS Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of Zhongshan Hospital, Fudan University.

Keywords: Sec62; tumour recurrence and metastasis; integrinα/CAV1 signalling; cell migration; HCC

Suggested Citation

Du, Juan and Zhao, Hetong and Liu, Dong and Liu, Hui and Chen, Jun and Cheng, Binbin and Zhai, Xiaofeng and Yin, Zifei and Zhang, Yani and Ling, Changquan, Sec62 Promotes Early Recurrence of Hepatocellular Carcinoma Through Activating Integrinα/CAV1 Signaling (June 17, 2019). Available at SSRN: https://ssrn.com/abstract=3405563 or http://dx.doi.org/10.2139/ssrn.3405563

Juan Du

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Shanghai
China

Hetong Zhao

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Shanghai
China

Dong Liu

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Shanghai
China

Hui Liu

Government of the People's Republic of China - Navy Military Medical University

Shanghai
China

Jun Chen

Fudan University - Liver Cancer Institute

Shanghai, 200032
China

Binbin Cheng

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Shanghai
China

Xiaofeng Zhai

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Shanghai
China

Zifei Yin

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Shanghai
China

Yani Zhang

Government of the People's Republic of China - Department of Traditional Chinese Medicine

Shanghai
China

Changquan Ling (Contact Author)

Government of the People's Republic of China - Department of Traditional Chinese Medicine ( email )

Shanghai
China

Click here to go to TheLancet.com

Paper statistics

Downloads
50
Abstract Views
695
PlumX Metrics